Shimizu K, Schönbeck U, Mach F, Libby P, Mitchell R N
Departments ofMedicine and Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Immunol. 2000 Sep 15;165(6):3506-18. doi: 10.4049/jimmunol.165.6.3506.
Although interruption of CD40-CD40L interactions via their respective mAbs yields prolonged allograft survival, the relative importance of CD40 or CD40L on donor or host cells remains unknown. Moreover, it is uncertain whether any allospecific tolerance occurring with CD40-CD40L blockade will also prevent allograft arteriopathy, the major long-term limitation to transplantation. Therefore, we performed cardiac transplantations using CD40L-deficient (CD40L-/-) mice to investigate the mechanisms underlying prolonged allograft survival. Without immunosuppression, wild-type (WT) hosts rejected allo-mismatched WT or CD40L-/- heart allografts within 2 wk. Conversely, allografts in CD40L-/- hosts beat vigorously for 12 wk. Anti-CD40 treatment did not induce graft failure in CD40L-/- recipients. Although graft-infiltrating cells were reduced approximately 50% in CD40L-/- hosts, the relative percentages of macrophages and T cell subsets were comparable to WT. IFN-gamma, TNF-alpha, and IL-10 were diminished commensurate with the reduced cellular infiltrate; IL-4 was not detected. CD40L-/- recipients did not develop IgG alloantibodies and showed diminished B7 and CD28 expression on subsets of graft-infiltrating cells. CD40L-/- transplant recipients developed allospecific tolerance to the donor haplotype; second set donor skin grafts engrafted well, whereas third-party skin grafts were vigorously rejected. By MLR, splenocytes from CD40L-/- allograft recipients also demonstrated allo-specific hyporesponsiveness. Nevertheless, allografts in CD40L-/- hosts developed significant graft arteriosclerosis by 8-12 wk posttransplant. Therefore, we propose that early alloresponses, without CD40-CD40L costimulation, induce allospecific tolerance but may trigger allo-independent mechanisms that ultimately result in graft vasculopathy.
尽管通过各自的单克隆抗体阻断CD40 - CD40L相互作用可延长同种异体移植物的存活时间,但CD40或CD40L在供体细胞或宿主细胞上的相对重要性仍不清楚。此外,尚不确定CD40 - CD40L阻断所产生的任何同种异体特异性耐受性是否也能预防同种异体移植动脉病变,这是移植的主要长期限制因素。因此,我们使用CD40L缺陷(CD40L - / -)小鼠进行心脏移植,以研究同种异体移植物长期存活的潜在机制。在没有免疫抑制的情况下,野生型(WT)宿主在2周内排斥了同种异体不匹配的WT或CD40L - / -心脏移植物。相反,CD40L - / -宿主中的移植物有力地跳动了12周。抗CD40治疗未在CD40L - / -受体中诱导移植失败。尽管CD40L - / -宿主中移植浸润细胞减少了约50%,但巨噬细胞和T细胞亚群的相对百分比与WT相当。IFN -γ、TNF -α和IL - 10与细胞浸润减少相应减少;未检测到IL - 4。CD40L - / -受体未产生IgG同种异体抗体,并且在移植浸润细胞亚群上显示出B7和CD28表达减少。CD40L - / -移植受体对供体单倍型产生了同种异体特异性耐受性;二次移植的供体皮肤移植物生长良好,而第三方皮肤移植物被强烈排斥。通过混合淋巴细胞反应(MLR),来自CD40L - / -同种异体移植受体的脾细胞也表现出同种异体特异性低反应性。然而,CD40L - / -宿主中的移植物在移植后8 - 12周出现了明显的移植动脉硬化。因此,我们提出,在没有CD40 - CD40L共刺激的情况下,早期同种异体反应诱导同种异体特异性耐受性,但可能触发同种异体非依赖性机制,最终导致移植血管病变。